Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
Although it is an uncommon and not standard strategy, previous ICI in nonmetastatic UC and a period of ≥12 months after previous ICI in the metastatic setting were associated with better outcomes after ICI rechallenge in patients with aUC.
Authors
- Hooman Ebrahimi (ORCID: https://orcid.org/0000-0001-5939-3185)
- Valentina Tateo (ORCID: https://orcid.org/0000-0002-1199-2338)
- A. Necchi
- Petros D. Grivas (ORCID: https://orcid.org/0000-0003-3965-3394)
- Nivedita Agarwal (ORCID: https://orcid.org/0000-0002-1387-9566)
- Philippe E. Spiess (ORCID: https://orcid.org/0000-0002-5723-1972)
- Ashish M. Kamat (ORCID: https://orcid.org/0000-0003-3546-9928)
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Antonio Cigliola (ORCID: https://orcid.org/0009-0005-7109-2429)
- Brigida Anna Maiorano (ORCID: https://orcid.org/0000-0001-5423-3158)
- Chiara Mercinelli (ORCID: https://orcid.org/0000-0003-1165-1776)
- Shilpa Gupta
- Nazlı Dizman (ORCID: https://orcid.org/0000-0002-3907-8513)
- Giovanni Luigi Pastorino
Institutions
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- Fred Hutch Cancer Center (US)
- City of Hope (US)
- IRCCS Ospedale San Raffaele (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105862
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00